Login / Signup

Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.

Saro H ArmenianYanjun ChenLindsay HagemanJessica WuWendy LandierAlysia Kristine BosworthLiton FranciscoElizabeth SchlichtingRavi BhatiaDonna SalzmanF Lennie WongDaniel J WeisdorfStephen J FormanMukta AroraSmita Bhatia
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The burden of severe/life-threatening conditions is substantially higher in BMT recipients when compared with an unaffected comparison group, contributing to an increasing incidence of non-RRM over time. Chronic graft-versus-host disease was an important risk factor for severe/life-threatening/fatal conditions among BMT recipients, informing the need for close monitoring to anticipate and manage morbidity.
Keyphrases
  • acute myeloid leukemia
  • risk factors
  • early onset
  • kidney transplantation
  • young adults
  • drug induced
  • allogeneic hematopoietic stem cell transplantation
  • stem cells
  • cell therapy
  • acute lymphoblastic leukemia